A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO). by Moore, Jason
RESEARCH ARTICLE Open Access
A prospective observational study of iron
isomaltoside in haemodialysis patients with
chronic kidney disease treated for iron
deficiency (DINO)
Ashraf I. Mikhail1* , Staffan Schön2, Sylvia Simon3, Christopher Brown1, Jörgen B. A. Hegbrant2, Gert Jensen4,
Jason Moore5 and Lennart D. I. Lundberg6
Abstract
Background: Iron deficiency is frequent in haemodialysis (HD) patients with chronic kidney disease (CKD), and
intravenous iron is an established therapy for these patients. This study assessed treatment routine, effectiveness,
and safety of iron isomaltoside (IIM) 5% (Diafer®) in a HD cohort.
Methods: This prospective observational study included 198 HD patients converted from iron sucrose (IS) and
treated with IIM according to product label and clinical routine. Data for IIM were compared to historic data for IS
in 3-month intervals. The primary endpoint was to show non-inferiority for IIM versus IS in haemoglobin (Hb)
maintenance.
Results: Most patients (> 60%) followed a fixed low-dose iron treatment protocol. Three minutes were required for
preparation and administration of IIM. Erythropoiesis-stimulating agent (ESA) was used in > 80% of patients during
both IIM and IS phases. The maintenance of Hb was similar with both iron drugs; the mean Hb level was 11 g/dL,
and the mean change of 0.3 g/dL (95% confidence interval: 0.1, 0.5) for IIM 0–3 months compared to IS
demonstrated non-inferiority. Nine adverse drug reactions were reported in 2% of patients administered IIM.
All patients had uneventful recoveries. The frequency of metallic taste was higher with IS compared to IIM
(34% versus 0.5%, p < 0.0001).
Conclusions: IIM is effective and well tolerated by CKD patients on HD. IIM was non-inferior to IS in maintenance of
Hb, and had similar ESA requirements. The fast-push injection of IIM may enable logistical benefits in clinical practice,
and the low frequency of metallic taste contributes to patient convenience.
Trial registration: ClinicalTrials.gov identifier NCT02301026, study registered November 25, 2014.
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Background
Iron deficiency is common in patients with chronic kidney
disease (CKD), and intravenous (IV) iron is the treatment
of choice for those on haemodialysis (HD) [1, 2]. HD pa-
tients with CKD may suffer from iron deficiency due to
continuous blood losses, treatment with erythropoiesis-sti-
mulating agents (ESAs), impaired absorption of iron by
medications such as gastric acid inhibitors and phosphate
binders, or impaired absorption of iron and its release from
iron stores in inflammation [1]. The amount of iron lost
in these patients as a result from blood loss in the
HD procedure, regular blood sampling, and occult in-
testinal bleeding due to uremic enteropathy, is esti-
mated to range from 0.5 to 2.8 g of iron per year
depending on if only dialysis-based or if other sources
of blood loss are also considered, including the influ-
ence of vascular access and comorbidities [3, 4]. Iron
deficiency, together with other factors such as insuffi-
cient erythropoietin production by the kidneys and
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hyporesponsiveness to erythropoietin, cause anaemia
in these patients [5, 6].
IV iron and ESAs are the cornerstones of anaemia
management in CKD patients receiving dialysis [1]. A
low-dose high-frequency IV iron treatment regimen is
recommended for adult HD patients (> 2 infusions, for
each infusion 100–200 mg iron) [2]. Much evidence indi-
cates that adequate iron supply is necessary to achieve
optimal responses to ESAs [1], and thereby potentially
avoid the risk of cardiovascular and fatal events associ-
ated with ESAs [7]. Appropriate treatment with IV iron
can allow a decrease in ESA dose in CKD patients [5],
and ESA-sparing IV iron therapies may reduce the costs
of anaemia management [8].
When prescribing IV iron treatment it is recom-
mended to first balance the potential benefits of redu-
cing blood transfusions, ESA use, and anaemia-related
symptoms, against the risk of adverse events associated
with parenteral iron preparations [1]. Of particular con-
cerns regarding the risk of adverse events are hypersen-
sitivity reactions and cellular toxicity associated with
catalytic/labile iron. Newer formulations of IV iron have,
however, demonstrated a low frequency of serious and
severe hypersensitivity reactions in several clinical trials
[9]. Furthermore, data indicate that IV irons that are
more stable with a lower labile iron release and that
cause less cell iron uptake have a reduced likelihood of
inducing cellular damage [10, 11].
Iron isomaltoside (IIM) 5% (Diafer®) is a low-dose
high-frequency IV iron indicated for the treatment of
iron deficiency in dialysis CKD patients. It consists of
iron and a carbohydrate moiety where the iron is tightly
bound in a matrix structure, which minimises the release
of labile iron and lowers the risk of iron toxicity [12, 13].
The tight iron binding also allows for fast-push injection.
In a previous randomised trial, IIM was found to have
comparative efficacy to iron sucrose (IS), and a good
safety profile similar to the short-term safety of IS in
CKD patients on HD [14]. The use of IS in the HD set-
ting is currently widespread, and this IV iron preparation
has a well-established efficacy and short-term safety pro-
file [15]. Concerning the long-term safety of IS, this re-
mains to be investigated in upcoming studies such as
the Proactive IV Iron Therapy in Dialysis Patients
(PIVOTAL) trial that aims to evaluate all-cause mortality
and non-fatal cardiovascular events for IS therapy in a
HD population with 2–4 years follow-up per patient
[16]. The safety profile of IS over a longer duration of
treatment may differ compared to IIM because IS has
been shown to release more labile iron [12, 17].
The DINO (DIafer NOn-interventional) study was
established to determine the treatment routine, effective-
ness, and safety of IIM in a contemporary HD cohort
with CKD converted from IS in clinical practice. The
treatment outcomes were compared with historic data
on IS therapy in the patients in 3-month intervals. The
primary endpoint was to demonstrate non-inferiority for
IIM versus IS in the maintenance of haemoglobin (Hb)
levels over the first 3 months.
Methods
Study design and population
This was a prospective, observational, multicentre study
conducted at five clinical sites across Sweden and the
United Kingdom (UK) between September 2014 and De-
cember 2016. Patients included were ≥ 18 years of age
and in a stable phase of CKD, had been on HD therapy
> 3months, and had received at least one dose of IS
treatment within the last 6 months before study start
while being on HD. Exclusion criteria were IIM contra-
indications, inability to give informed consent, primary
disease other than CKD and likely to impact the study
results, inability to estimate retrospective data for IS
treatment, and planned change of iron dosing protocol
or routines during the study. The study design is shown
in Fig. 1. Patients entering the study had to have retro-
spective 3-month data for IS therapy within month − 9
to month 0 from the start of the prospective phase. The
IS that had been used was Venofer® (study centres
personal communications). IIM was given as standard
treatment according to the product label and local clin-
ical practice, and was generally administered undiluted
(50 mg/mL solution) as a fast-push injection into the
venous limb of the dialyser. Most patients were observed
for 12 months after the first treatment. All patients were
treated and followed according to the local guidelines in
each centre. At each participating centre, a senior neph-
rologist was responsible for the conduct of the study.
Fig. 1 Study design. IIM = iron isomaltoside; IS = iron sucrose
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Data collection and outcome measures
Data for iron treatment routine and dosing, blood tests,
concomitant anaemia medications (ESAs, blood transfu-
sion, and cobalamin and/or folic acid), and adverse drug
reactions (ADRs) were collected from the medical re-
cords. The data collection was done prospectively for
the IIM study phase and retrospectively for the historic
IS phase. All blood tests were analysed locally at each
participating centre. ADRs during the prospective IIM
study phase were registered and reported in accordance
with the national reporting systems. ADRs registered in
the IIM study were also reported to the Sponsor’s phar-
macovigilance department. For ADRs during the IS
phase, only recorded events of metallic taste were col-
lected. The collected data were systematically entered
into an electronic case report form (eClinicalOS, Merge
Healthcare, NC, USA; licensed by BioStata ApS,
Denmark).
The primary endpoint was to demonstrate
non-inferiority for maintenance of Hb levels over the
first three months of IIM treatment compared to the
historic 3-month phase with IS. Key secondary end-
points included assessments of iron and ESA dosing, la-
boratory parameter changes and maintenance, and
frequency of ADRs.
Statistical methods
Data analyses were conducted on the safety analysis set
(n = 198), which included all patients who were enrolled
in the study according to the protocol criteria and who
received at least one dose of IIM, and on the effective-
ness analysis set (n = 195), which included all patients in
the safety analysis set who received at least one dose
each of IIM and IS with at least one Hb measure
post-treatment.
Data are presented as mean and standard deviation
(SD) and as median and interquartile range (IQR) for
continuous variables, and number of exposed patients
(with proportions) for categorical variables. Data for IIM
in 3-month intervals, 0–3 months, 3–6 months, 6–9
months and 9–12 months, of the prospective study were
compared to cross-over retrospective data over 3 months
for IS. For the primary endpoint analysis, non-inferiority
for the mean Hb change for IIM treatment 0–3 months
compared to the IS phase was determined using the
95% two-sided confidence interval (CI) and a margin of
− 0.15 g/dL. Non-inferiority was declared if the lower
limit of the 95% CI was above − 0.15. P-values for iron
and ESA dosing and blood parameter levels were obtained
from the Wilcoxon rank-sum test by comparisons of the
IIM phases to the IS phase. P-values for comparisons of
number of patients with metallic taste events between
the IIM and IS phases were obtained from the McNemar
test. The significance cut-off for all analyses was p < 0.05.
All data were analysed using SAS version 9.4 (SAS insti-
tute, USA).
Ethical considerations
The Regional Ethics Committees (RECs) in Sweden
(EPN Lund; application number: 2014/306; approval
date: 8th May 2014), and in the UK (East of Scotland
Research Ethics Service; REC reference: 14/ES/1075;
IRAS project ID: 159035; approval date: 23rd September
2014) approved the study. In the UK, local Research &
Development permission was obtained from each par-
ticipating centre prior to the start of the study. The
study was registered with the ClinicalTrials.gov registry
(NCT02301026). All study participants gave written in-
formed consent before inclusion into the study, and the
study was performed in accordance with the Declaration
of Helsinki and the European Medicines Agency criteria
for non-interventional studies [18].
Results
Study population
The details of patient disposition are outlined in Fig. 2. A
total of 209 CKD patients on HD were screened for eligi-
bility. Of the 204 patients enrolled, 159 (78%) patients
completed the 12-month study and 45 (22%) patients
discontinued. Patient demographics and baseline charac-
teristics are presented in Table 1. The safety analysis set
included 198 patients of whom the majority were male (n
= 131; 66%), and 84% of the patients (n = 166) had re-
ceived IIM treatment prior to study participation during a
mean (SD) time of 3.8 (2.4) months from the last IS dose.
Iron treatment
The majority of patients (> 60%) followed a fixed
low-dose iron treatment regimen across all 3-month
periods of the IIM study and during the historic IS
phase. IIM was generally administered undiluted as a
fast-push injection with a mean (SD) time of around 1.0
(0.7) minute per treatment occasion. A mean (SD) time
of around 2.9 (1.0) minutes were used for both prepar-
ation and intradialytic administration of IIM per treat-
ment occasion. The mean number of iron doses and
mean cumulative iron doses administered to patients did
not differ significantly between the IIM and IS treatment
phases (Table 2). Each patient received on average
around 5 × 100 mg iron in each 3-month period. The
mean (SD) cumulative iron dose monthly per patient
was between 167.7 (89.1) and 187.0 (101.9) mg across all
3-month periods with IIM treatment, and was 178.1
(98.9) mg with IS treatment (Table 2).
Concomitant anaemia medication
Concomitant medications for anaemia correction during
the IIM and IS phases were similar and included ESAs
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(> 80% of patients across all 3-month periods; Table 2),
cobalamin and/or folic acid (around 50% of patients
across all 3-month periods), and blood transfusion (3–
6% of patients across all 3-month periods).
For patients treated with ESAs, the mean number of
doses given per patient over 3 months and the mean cu-
mulative dose given per patient weekly did not differ sig-
nificantly when comparing the IIM and IS treatment
phases (Table 2).
Effectiveness
Table 3 presents the mean levels and changes of Hb, fer-
ritin, transferrin saturation (TSAT), and C-reactive pro-
tein (CRP) in each 3-month interval of the IIM and IS
treatment phases. The effectiveness of IIM was compar-
able to that of IS with similar mean levels of Hb and
iron parameters over the 3-month periods.
The mean Hb level was around 11 g/dL for both iron drug
phases. The primary endpoint analysis demonstrated that
IIM was non-inferior to IS in maintenance of Hb levels. The
mean (SD) change in Hb was 0.3 (1.2) g/dL (95% CI: 0.1,
0.5) when comparing the IIM 0–3month period to the IS
phase (Table 3 and Fig. 3). Non-inferiority to IS in Hb main-
tenance was also achieved for the IIM 3–6 and 9–12month
periods (Fig. 3). The percent distribution of all Hb values
across different Hb ranges in a 3-month interval was similar
between the IIM 3-month periods and the IS phase (Fig. 4a),
and was based on 526 Hb measures for IS, 579 Hb measures
for IIM 0–3months, 536 Hb measures for IIM 3–6months,
510 Hb measures for IIM 6–9months, and 487 Hb mea-
sures for IIM 9–12months. Most Hb values (62–68%) were
maintained within the target range of 10–12 g/dL (including
both values) with both iron treatments, and around 13% of
the Hb values were < 10 g/dL. The maintenance of iron
Fig. 2 Patient flow diagram (based on CONSORT 2010). Hb = haemoglobin; IIM = iron isomaltoside; IS = iron sucrose
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parameters with IIM compared to IS treatment was also
similar. Approximately half of the patients had mean
ferritin and TSAT levels within the desired ranges of
200–500 μg/L and 20–30% respectively (including both
values), with both iron treatments (Fig. 4b and c).
Around 30% of the patients had a mean ferritin level >
500 μg/L, but for most of these patients the mean ferritin
level did not reach 800 μg/L (Fig. 4b). Between 20 and 30%
of the patients had a mean TSAT level > 30% (Fig. 4c), and
the maximum level across the 3-month periods was
around 70% (Data on file, Pharmacosmos A/S, Denmark).
The median (IQR) level of CRP was slightly elevated dur-
ing the IIM phase compared to the IS phase (9 [5–22] mg/L
for IIM 0–3months, 10 [6–22] mg/L for IIM 3–6months,
10 [5–20] mg/L for IIM 6–9months, and 10 [5–23] mg/L
for IIM 9–12months versus 7 [3–15] mg/L for the IS phase,
p < 0.05; Table 3). Sub-analyses of CRP levels for each indi-
vidual site in the study demonstrated that two of the five
centres, in particular one of them, contributed to the ob-
served increase in CRP between the IIM and IS phases
(Data on file, Pharmacosmos A/S, Denmark).
Safety
A total of 9 ADRs were reported in 4/198 (2%) of the
patients who were treated with IIM. Two of these ADRs
were reported as serious (burning sensation in the face,
Table 2 IV iron and ESA treatments
Retrospective IS phase Prospective IIM phases
0–3 months 0–3 months 3–6 months 6–9 months 9–12 months
IV iron treatment n = 195 n = 195 n = 171 n = 156 n = 151
Number of IV iron doses per patient
Mean (SD) 5.4 (3.0) 5.6 (3.1) 5.1 (2.8) 5.0 (2.7) 5.2 (3.0)
p-valuea 0.4664 0.3533 0.2313 0.5874
Cumulative IV iron dose (mg) per patient
Mean (SD) 534.4 (296.7) 561.0 (305.8) 515.2 (283.1) 503.2 (267.2) 528.5 (301.2)
Mean (SD) monthly 178.1 (98.9) 187.0 (101.9) 171.7 (94.4) 167.7 (89.1) 176.2 (100.4)
p-valuea 0.3071 0.5650 0.3530 0.8036
ESA treatment n = 195 n = 195 n = 171 n = 156 n = 151
Patients with ESA, n (%) 175 (89.7) 163 (83.6) 153 (89.5) 143 (91.7) 140 (92.7)
Number of ESA doses per patient
Mean (SD) 19.4 (11.1) 17.5 (11.7) 20.1 (12.3) 18.6 (11.3) 20.1 (12.5)
Median (IQR)b 14.0 (12.0–26.0) 14.0 (8.0–25.0) 17.0 (10.0–29.0) 15.0 (9.0–26.0) 16.0 (9.0–32.0)
p-valuea 0.0468 0.9228 0.2840 0.8250
Cumulative ESA dose (1000 IU) weekly per patient
Mean (SD) 8.0 (8.1) 7.4 (6.5) 8.7 (8.0) 9.0 (9.3) 8.9 (7.4)
Median (IQR)b 6.0 (3.3–10.7) 5.7 (2.7–10.0) 6.7 (2.9–12.0) 6.0 (3.0–10.8) 7.0 (3.0–11.0)
p-valuea 0.4131 0.5745 0.8107 0.3248
aP-value obtained from Wilcoxon rank-sum test by comparison to the retrospective IS phase
bData not normally distributed are presented as median values
ESA erythropoiesis-stimulating agent, IIM iron isomaltoside, IQR interquartile range, IS iron sucrose, IU international unit, IV intravenous, n number of patients, SD
standard deviation
Table 1 Patient demographics and IV iron treatment characteristics
at baseline
Total population
(n = 198)
Patient demographics
Gender, n (%)
Female 67 (33.8)
Male 131 (66.2)
Age (years)
Mean (SD) 70.3 (13.0)
Weight (kg)
Mean (SD) 78.2 (19.7)
IV iron treatment characteristics at baseline
Time between last IS treatment and start
of IIM prospective study phasea (months)
Mean (SD) 3.8 (2.4)
Patients with previous IIM treatment,b n (%) 166 (83.8)
aStart of IIM prospective study phase determined by the date of informed
consent. bIIM treatment after the last IS treatment and before start of the IIM
prospective study phase
IIM iron isomaltoside, IS iron sucrose, IV intravenous, n number of patients, SD
standard deviation
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pruritus, back pain and vomiting in one patient, and
upper abdominal pain, chills, pyrexia and nausea in an-
other patient), and the rest were reported as not serious
(headache in one patient, and 6 events of metallic taste
in another patient). All patients had an uneventful re-
covery. The two patients who experienced a serious
ADR discontinued the study.
The 6 events of metallic taste with IIM treatment re-
ported in a single patient occurred out of a total of 3528
IIM administrations (0.2%) in the study. Five of these
events took place during the first three months of IIM
treatment and one event took place during the 6–9
month period of the study. The single patient who expe-
rienced metallic taste with IIM treatment had a history
of frequent metallic taste events when administered IS
(study nurse personal communication). The frequency of
patients reporting metallic taste was significantly higher
when treated with IS during the historic phase compared to
when treated with IIM during the prospective study phase
(34% [67/198] versus 0.5% [1/198], p < 0.0001; Table 4).
Discussion
This prospective observational study of IIM treatment in
clinical practice demonstrates effective maintenance of
Hb levels and adequate iron status with a good safety
profile in CKD patients on HD converted from IS. When
comparing IIM and IS therapies, both iron preparations
showed similar effectiveness in maintaining Hb and iron
Table 3 Laboratory parameters
Retrospective IS phase Prospective IIM phases
0–3 months 0–3 months 3–6 months 6–9 months 9–12months
Hb (g/dL) n = 195 n = 195 n = 183 n = 178 n = 166
Hb level
Mean (SD) 11.1 (1.0) 11.4 (0.9) 11.2 (1.0) 11.1 (1.1) 11.2 (0.9)
p-valuea 0.0151 0.4154 0.8695 0.7934
Hb change vs. IS phase
Mean (SD) 0.3 (1.2) 0.1 (1.3) 0.0 (1.4) 0.0 (1.2)
Ferritin (μg/L)
Ferritin level n = 187 n = 190 n = 182 n = 175 n = 159
Mean (SD) 395.5 (231.4) 395.1 (224.3) 420.4 (224.3) 408.4 (231.1) 420.8 (253.1)
Median (IQR)b 366.7 (227.5–519.0) 364.3 (222.7–523.0) 391.5 (261.3–553.3) 356.0 (236.7–549.0) 390.0 (223.0–590.0)
p-valuea 0.9135 0.1799 0.5429 0.4434
Ferritin change vs. IS phase n = 184 n = 175 n = 168 n = 152
Mean (SD) 4.2 (180.4) 28.4 (209.0) 9.6 (206.7) 16.8 (217.5)
Median (IQR)b −20.3 (−93.7–93.4) 9.8 (−86.2–159.0) −5.3 (−102–124.7) 4.7 (− 88.9–129.5)
TSAT (%)
TSAT level n = 187 n = 191 n = 182 n = 175 n = 159
Mean (SD) 25.0 (8.8) 26.8 (9.8) 26.4 (10.2) 26.2 (9.7) 26.7 (10.0)
p-valuea 0.0592 0.4014 0.2828 0.1517
TSAT change vs. IS phase n = 185 n = 175 n = 168 n = 152
Mean (SD) 1.8 (9.4) 1.0 (8.5) 0.9 (9.4) 1.3 (9.8)
CRP (mg/L)
CRP level n = 139 n = 129 n = 109 n = 122 n = 117
Mean (SD) 12.4 (14.8) 21.6 (35.1) 19.5 (25.5) 19.4 (27.9) 18.8 (23.6)
Median (IQR)b 7.0 (3.3–15.3) 8.7 (4.9–22.0) 10.0 (6.0–21.5) 10.0 (4.7–19.5) 10.0 (5.0–23.0)
p-valuea 0.0351 0.0030 0.0143 0.0131
CRP change vs. IS phase n = 124 n = 104 n = 112 n = 108
Mean (SD) 8.9 (33.9) 6.8 (21.8) 6.3 (19.9) 7.2 (21.6)
Median (IQR)b 0.8 (−1.5–7.0) 2.6 (−0.8–7.8) 1.6 (−1.1–10.8) 1.4 (−1.5–11.2)
aP-value obtained from Wilcoxon rank-sum test by comparison to the retrospective IS phase
bData not normally distributed are presented as median values
CRP C-reactive protein, Hb haemoglobin, IIM iron isomaltoside, IQR interquartile range, IS iron sucrose, IU international unit, IV intravenous, n number of patients,
SD standard deviation, TSAT transferrin saturation
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parameter concentrations in the patients, with similar
doses and ESA requirements. The primary endpoint was
achieved and IIM demonstrated non-inferiority to IS in
maintenance of Hb levels in the patients.
The treatment frequency and cumulative iron doses ad-
ministered to the patients were comparable between the
IIM and IS phases, and mainly followed a fixed low-dose
treatment regimen given at regular intervals. Clinical
guidelines recommend a low-dose high-frequency IV iron
treatment protocol for adult HD patients who are iron
deficient and receive ESA therapy [2]. For drugs given fre-
quently it is advantageous to have a short duration of time
for the handling and administration. The time for both
preparation and injection of IIM into the dialysis circuit
was on average 3min. Although not assessed in this study,
the ability to rapidly prepare and administer IIM as a
fast-push injection is anticipated to enable logistical bene-
fits in clinical practice, and this is likely to translate into
efficiencies for HD departments using this drug.
The pattern of ESA use did not change over time in
the IIM study or when compared to the IS phase prob-
ably because the iron protocol remained the same. This
shows that ESA and IV iron were tightly co-medicated
for the treatment of anaemia in this HD cohort. IIM and
IS were equally effective in keeping the Hb levels, and
the Hb values were generally within the target range of
10–12 g/dL during both iron treatment phases. A pro-
portion of the Hb values were, however, below 10 g/dL
with both iron treatments, which indicates suboptimal
management of the anaemia for some of the patients.
When correcting anaemia with iron supplementation in
adult CKD patients on ESA therapy, it is recommended to
keep the ferritin level ≤ 500 μg/L [1] or ≤ 800 μg/L with a
review of the iron dose when the ferritin level reaches
500 μg/L [2]. About 50% of the patients in this study main-
tained a mean ferritin level between 200 and 500 μg/L, and
to a lesser extent between 500 and 800 μg/L, while a small
percentage (< 10%) of the patients had a mean ferritin
level ≥ 800 μg/L during the IIM and IS treatment phases.
The high level of ferritin in these patients may reflect active
inflammation or may have resulted from blood transfusions
given to patients who had a very low level of Hb. High
levels of ferritin in HD patients have been reported previ-
ously. In the 1-year Dialysis Outcomes and Practice
Patterns Study (DOPPS) Practice Monitor conducted be-
tween 2010 and 2011, data for anaemia care collected from
up to 120 HD facilities in the United States showed that the
ferritin levels exceeded 800 μg/L in at least half of the
patients in over a quarter of these facilities [19]. By 2011,
the serum ferritin concentration was ≥800 μg/L in 34% of
the patients, and was > 1200 μg/L in 11% of the patients.
Ferritin is commonly used as a marker to monitor the
iron status in patients, but as an acute phase reactant its
blood level increases in systemic inflammation inde-
pendently of body iron stores. Non-invasive techniques,
such as quantitative magnetic resonance imaging (MRI),
provide a more direct and accurate measure of body
iron stores [4]. In previous MRI studies, the liver iron
concentration in HD patients treated with IV iron was
found to correlate with the administered iron dose, but
inconsistently with the serum ferritin level [20–22]. Fur-
thermore, hepatic iron overload detected with MRI was
reported in a French HD cohort of 119 patients when
treated with IS according to current guideline recom-
mendations (ferritin target range 200–500 μg/L) [22]. In
this HD cohort, 84% of the patients had a liver iron
Fig. 3 Mean Hb changes for the IIM prospective phases versus the IS retrospective phase. Non-inferiority was achieved for the primary endpoint
comparison of IIM 0–3months to IS where the lower limit of the 95% CI was above the margin of − 0.15 g/dL. CI = confidence interval; Hb = haemoglobin;
IIM = iron isomaltoside; IS = iron sucrose
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concentration corresponding to mild, moderate or se-
vere hepatic iron overload (cut-off > 50 μmol/g dry
weight).
Iatrogenic iron overload longer term may be associated
with an increased risk of cardiovascular events and mor-
tality in HD patients [4]. This has led to questioning of
the safety of contemporary IV iron dosing protocols in
the HD setting. In the current study, the mean cumula-
tive monthly doses of IIM ranged from 168 to 187 mg,
and the majority of the Hb values were maintained
within the target range of 10–12 g/dL. This iron dosing
is rather modest in relation to the UK guideline
Fig. 4 Percent distribution of all Hb values across Hb ranges (a), percent patient distribution across ferritin ranges based on individual mean
values (b), and percent patient distribution across TSAT ranges based on individual mean values (c). The maintenance of Hb and iron parameters
with IIM compared to IS treatment was similar. Hb = haemoglobin; IIM = iron isomaltoside; IS = iron sucrose; TSAT = transferrin saturation
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recommendation for iron maintenance therapy in HD
patients of 50–60 mg IV iron per week (200–240 mg
monthly) [2]. It is, however, higher than the very conser-
vative strategy advocated by the Japanese guidelines of
40 mg IV iron per week (160 mg monthly) for HD pa-
tients in a cycle of 13 administrations, while keeping the
serum ferritin level < 300 μg/L [23]. From a safety per-
spective, the mean cumulative monthly doses of IIM ad-
ministered to the patients in this study to maintain a
stable Hb are below IV iron dose levels of ≥200 or ≥ 300
mg per month that have been found in recent long-term
(1–2 years) epidemiological studies to be associated with
an increased risk of morbidity and mortality in HD
patients [24, 25]. Furthermore, IS doses of > 250 mg per
month have been reported to be associated with an in-
creased risk of hepatic iron overload, as determined with
MRI in a French study in 199 HD patients [26].
The CRP levels in the present study were found to be
slightly higher during the IIM treatment phase com-
pared to the IS treatment phase. Sub-analyses revealed
that the difference in CRP levels between the iron drug
phases was, however, only observed for two of the five
participating centres, and the centre for which this dif-
ference was most evident had the largest number of
patients in the study. Thus, this effect was mainly de-
rived from one centre that also had the greatest contri-
bution of patients in the study. The reason for this trend
is unclear but may have been attributed to concomitant
diseases or the dialysis process per se. It is unlikely to
have resulted from the iron treatment because the iron
dosing and levels of iron parameters were similar be-
tween the IIM and IS phases.
In this 12-month study, IIM demonstrated a good
safety profile, consistent with the findings from other
clinical studies of IIM in CKD patients on dialysis [5, 9,
14, 27]. Only one patient experienced metallic taste dur-
ing the IIM treatment phase. The patient reported me-
tallic taste at several occasions, but had a known history
of frequent metallic taste events when administered IS.
In this study cohort, IIM was associated with a signifi-
cantly reduced frequency of metallic taste sensation
compared to IS, which is likely to be desirable to pa-
tients. In a previous randomised trial comparing the
treatment effects of IIM and IS in patients with iron
deficiency anaemia, the frequency of patients reporting
dysgeusia that mainly consisted of metallic taste (Data
on file, Pharmacosmos A/S, Denmark) was lower in the
IIM group (0.6%) than in the IS group (2.4%) [28], pro-
viding further evidence for a difference in taste sensation
between the two iron drugs. The impact of the differ-
ence in metallic taste frequency between IIM and IS in
the present study is unknown. The metallic taste could
turn out to be a surrogate indicator for labile iron
release, but this is unproven and requires investigation.
The tight binding of iron to the carbohydrate moiety
in IIM, allows a controlled and slow release of iron to
iron-binding proteins, which may have potential benefit
to minimise labile iron toxicity. Less stable IV iron prep-
arations are at increased risk of triggering toxicity such
as oxidative stress, renal injury, and endothelial damage,
as demonstrated in studies with CKD patients treated
with IS [29, 30]. Iron-induced oxidative stress and endo-
thelial dysfunction may promote atherosclerosis with in-
creased risks of cardiovascular morbidity and mortality
in HD patients [31]. There is, however, overall conflict-
ing data for an association between IV iron treatment
and elevated risk of cardiovascular adverse outcomes
due to oxidative stress in HD patients [32].
Another area of controversy is the concern of
increased infection risk with IV iron therapy caused by
enhanced bacterial growth and altered host immunity
[33]. While some studies have reported a link of usage,
dose-dependent risk or frequency-dependent risk be-
tween IV iron and infection or infection-related fatalities
in CKD patients, other studies have not confirmed such
a link [32]. A study in dialysis patients comparing differ-
ent IV irons found that less stable preparations such as
IS have an immunomodulatory effect leading to reduced
macrophage function in contrast to more stable prepara-
tions, such as IIM, that do not show this effect [34]. The
clinical relevance of this finding on infectious complica-
tions in patients on dialysis receiving repeated adminis-
trations of less stable IV iron formulations remains to be
explored.
In this study, each patient served as its own compara-
tor for the IIM vs IS treatment. The use of a historic
treatment phase can be subject to confounding due to
time effects. However, since the patients were in a stable
Table 4 Frequency of metallic taste
Retrospective IS phase Prospective IIM phases
0–3 months 0–3 months 3–6 months 6–9 months 9–12 months
n = 198 n = 198 n = 172 n = 157 n = 152
Patients with metallic taste, n (%) 67 (33.8) 1a (0.5) 0 (0.0) 1a (0.6) 0 (0.0)
p-valueb < 0.0001 NA < 0.0001 NA
aSame patient
bP-value obtained from McNemar test by comparison to the retrospective IS phase
IIM iron isomaltoside, IS iron sucrose, NA not applicable, n number of patients
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phase of the disease and the duration of the study was
relatively short, the use of such a historic treatment
phase seemed reasonable. For each patient, the analysis
was based on data aggregated in 3-month periods, where
the average of all measurements in each period was
used. Such an approach may cause regression of values
to the mean when assessing the average and range out
of averages for a population, but was deemed feasible for
this study given that the patients were on stable HD and
anaemia management and thus no large intra-individual
variability in the data across 3 months was expected.
Data for ADRs reported during the historic IS treatment
phase were generally considered difficult to access and
follow up. The comparison of the safety profiles for IIM
and IS was therefore limited to “yes or no” data for pa-
tients experiencing metallic taste to minimise the risk of
inaccuracies for the retrospective IS data collection.
Conclusions
In conclusion, this study shows that IIM is as effective
as IS in managing iron deficiency anaemia in CKD
patients on HD, and that it has a good safety profile.
The fast-push injection of IIM is predicted to enable
logistical benefits in clinical practice, and the low fre-
quency of metallic taste events further contributes to the
patient convenience.
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